S&P 500 Healthcare Sector SEC Filings — May 05, 2026

05-05-2026

On April 30, 2026, the Board of Directors of Core Scientific, Inc. appointed Jorge Ray, age 43, as Principal Accounting Officer, effective May 7, 2026; he has served as Chief Accounting Officer since March 2026. Mr. Ray brings extensive experience, including roles as Corporate Controller at Raymond James Financial, Inc. (April 2025–March 2026) and Executive Vice President and Chief Accounting Officer at BankUnited, Inc. (May 2017–April 2025), along with prior work at KPMG LLP and PricewaterhouseCoopers LLP. His compensation package includes an annual base salary of $400,000, target bonus opportunity of 40% of base salary, a one-time $600,000 restricted stock unit grant vesting over three years, and a $193,000 signing bonus (including $71,000 for relocation).

• ·Jorge Ray holds a Master of Business Administration from the MIT Sloan School of Management.
• ·No arrangements or understandings with other persons for the appointment; no family relationships with directors or executive officers; no disclosable transactions under Item 404(a) of Regulation S-K.

05-05-2026

BrightView reported Q2 FY26 net service revenues up 6.1% YoY to $702.9 million, driven by 4.0% growth in Landscape Maintenance revenue to $333.0 million and 28.5% surge in Snow Removal to $221.6 million, achieving record Adjusted EBITDA of $79.1 million (up 7.6%, margin 11.3%). However, net income declined 73.4% to $1.7 million (margin 0.2%), and Development Services revenue fell 13.0% to $149.6 million with Adjusted EBITDA down 44.2% (margin 6.4%). The company raised FY26 total revenue guidance to $2.745-$2.795 billion and Land Maintenance to +2% to +3% growth, but lowered Development Services to -5% to 0%; it also repriced its revolving credit facility and repurchased 1.1 million shares.

• ·6M FY26 net cash provided by operating activities $82.3M, down 45.7% YoY
• ·6M FY26 Adjusted Free Cash Flow $(24.5)M, down from $67.0M inflow YoY
• ·6M FY26 capital expenditures $113.5M, up 23.0% YoY (8.6% of revenue)
• ·Total Net Financial Debt to Adjusted EBITDA ratio 2.5x as of March 31, 2026 (up from 2.3x at Sep 30, 2025)
• ·FY26 Development Services revenue guidance revised down to ~ (5%) to ~ 0% from ~ 0% to ~ +2%

05-05-2026

Pacira BioSciences issued a letter to stockholders highlighting successful execution of its 5x30 strategy, with 2025 total revenues of $726.4 million, stock up over 30% since launch, and Q1 2026 revenue of $177 million (+5% YoY), driven by EXPAREL net sales of $143.3 million (up from $136.5 million), ZILRETTA +15% to $26.8 million, and iovera° +21% to $6.2 million. The company reported Adjusted EBITDA of $40.2 million and $202 million in cash for Q1 2026, while urging shareholders to vote 'FOR' its nominees (Christopher Christie, Samit Hirawat, MD, Thomas Wiggans) on the BLUE proxy card against DOMA Perpetual's nominees ahead of the June 9, 2026 Annual Meeting.

• ·Annual Meeting scheduled for June 9, 2026; record date April 22, 2026.
• ·EXPAREL 2025 volume-limited settlement in April 2025 resolves patent litigation.
• ·21 Orange Book-listed patents for EXPAREL.
• ·Phase 3 ZILRETTA shoulder OA topline results expected end of 2026; iovera° spasticity study topline end of 2026; PCRX-201 Phase 2 knee OA Part A readout in 2026.
• ·LG Chem EXPAREL revenues expected starting 2027 into mid-2040s.
• ·PCRX-2002 patent protection to 2042.

05-05-2026

Boston Scientific Corporation filed its Fourth Restated Certificate of Incorporation on May 5, 2026, restating and amending its charter to authorize 2,050,000,000 total shares, including 2,000,000,000 shares of Common Stock ($0.01 par value) and 50,000,000 shares of Preferred Stock ($0.01 par value). The document details governance provisions such as board authority to issue preferred stock series, stockholder meeting requirements, director election and removal processes, indemnification protections, and restrictions on stock repurchases from 5%+ shareholders. No financial performance metrics or material changes impacting operations are disclosed.

• ·Original Certificate of Incorporation filed June 22, 1979.
• ·Registered office: 251 Little Falls Drive, Wilmington, County of New Castle, Delaware 19808.
• ·Special meetings of stockholders callable only by Chairman, President, or majority of Whole Board.
• ·Stock repurchases from 5%+ owners limited to average closing price over prior 20 trading days unless approved by majority of Disinterested Stockholders.

05-05-2026

Editas Medicine reported Q1 2026 net loss of $25.0 million ($0.26 per share), a significant improvement from $76.1 million ($0.92 per share) in Q1 2025, driven by reduced R&D expenses ($17.6 million, down 34% YoY) and G&A ($10.2 million, down 24% YoY) following headcount reductions and reni-cel discontinuation, though collaboration revenues declined 39% YoY to $2.8 million. The company advanced EDIT-401 preclinical studies, showing >90% LDL-C reduction and cuts in Lp(a)/ApoB in non-human primates, remaining on track for first-in-human trial initiation later in 2026 with proof-of-concept data by year-end. Cash and equivalents stood at $123.6 million as of March 31, 2026, down from $146.6 million at year-end 2025, providing runway into Q3 2027.

• ·U.S. PTO reaffirmed Broad Institute's priority in CRISPR/Cas9 interference on March 26, 2026; CVC retains appeal right.
• ·GLP toxicology study in non-human primates ongoing for EDIT-401 to support first-in-human trial.
• ·Plans to present EDIT-401 data at ASGCT (May 11-15, 2026), TIDES USA (May 11-14, 2026), EAS Congress (May 24-27, 2026), NLA Sessions (June 11-14, 2026).
• ·Investor presentation at 2026 Jefferies Global Healthcare Conference on June 4, 2026.

05-05-2026

Precision BioSciences reported Q1 2026 revenues of $10.8 million, a significant increase from less than $0.1 million in Q1 2025, driven by a milestone payment from TG Therapeutics and legacy collaboration revenue. Net loss improved to $18.4 million ($(0.75) per share) from $20.6 million ($(2.21) per share) YoY, with R&D expenses down 3.7% to $13.1 million and G&A down 20.9% to $6.8 million, though offset by $9.4 million in other expenses versus $1.5 million income prior year. Cash balance of $125.8 million is expected to fund PBGENE-HBV and PBGENE-DMD milestones through 2028, amid clinical progress including 16 patients dosed in ELIMINATE-B and first site activation for FUNCTION-DMD.

• ·PBGENE-HBV late-breaking poster accepted at EASL Congress 2026 (May 27-30, Barcelona).
• ·PBGENE-DMD received FDA IND clearance, Fast Track designation, and Orphan Drug Designation; first site (Arkansas Children’s Hospital) activated.
• ·Clinical Trial Application approved for ELIMINATE-B expansion into France and Romania; patient screening expected Q2 2026.
• ·Two USPTO Notices of Allowance for PBGENE-HBV patents expiring November 2044.
• ·iECURE to present OTC-HOPE data at ASGCT (May 11-15, 2026) and SIMD (May 17-20, 2026).

05-05-2026

MFA Financial reported a GAAP net loss of $11.4 million, or ($0.11) per share, for Q1 2026 ended March 31, 2026, while distributable earnings were $31.1 million ($0.30 per share) and distributable earnings prior to realized credit losses reached $35.5 million ($0.34 per share), with a $0.36 per share dividend paid. The residential investment portfolio grew $203 million to $12,508 million QoQ from $12,305 million, driven by $1,064 million in acquisitions and originations including $392.8 million Agency MBS and $470.6 million Non-QM loans, and Lima One mortgage banking income rose 34% QoQ to $7.7 million. However, total economic return was -1.2%, 60+ day delinquencies increased to 7.8% from 7.1% QoQ (later declining to 7.3%), net interest spread narrowed to 1.64% from 1.69% QoQ, and portfolio runoff was $698 million.

• ·Debt/Net Equity Ratio 6.3x and recourse leverage 2.7x at March 31, 2026.
• ·Completed two Non-QM securitizations collateralized by $757.2 million UPB, bringing total securitized debt to $6.3 billion.
• ·Portfolio runoff of $698.0 million, including $80.9 million newly-originated SFR loans sold and 68 REO properties sold for $18.2 million net proceeds.
• ·Acquired $392.8 million Agency MBS, bringing position to $3.5 billion; entered $300.0 million TBA forward contracts.
• ·Lima One funded $130.2 million new business purpose loans and $70.4 million draws on transitional loans.

05-05-2026

IDEAYA Biosciences reported positive topline results from the Phase 2/3 OptimUM-02 trial of darovasertib + crizotinib in first-line HLA*A2-negative mUM, meeting primary endpoint with median PFS of 6.9 months vs 3.1 months (HR 0.42, 58% risk reduction) and ORR of 37.1% vs 5.8%; NDA submission planned for H2 2026 under FDA RTOR. Cash position stood at $972.9 million as of March 31, 2026, with runway into 2030 unchanged. However, Q1 2026 net loss widened to $98.5 million from $83.3 million in Q4 2025, driven by R&D expenses rising 10.5% to $95.7 million and collaboration revenue declining 39.4% to $6.6 million.

• ·Deprioritizing clinical activity with Gilead for IDE397 + Trodelvy combination and concluding enrollment in MTAP-deleted urothelial and lung cancers trial.
• ·Discontinuing development of IDE275 and IDE705 following GSK collaboration termination, evaluating strategic options.
• ·OptimUM-11 Phase 3 trial initiation expected H1 2026; OptimUM-10 full enrollment by end-2027.

05-05-2026

Glacier Bancorp, Inc. (GBCI) filed a Form 8-K on May 5, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, announcing an investor presentation made that day and posted on its website. The presentation is furnished as Exhibit 99.1. No financial metrics or performance data are disclosed in the filing text itself.

05-05-2026

Oaktree Specialty Lending reported total investment income of $70.4 million ($0.80 per share) for Q2 FY2026 ended March 31, 2026, down from $75.1 million ($0.85 per share) in Q1 FY2026 and $77.6 million ($0.90 per share) YoY, primarily due to lower reference rates and non-recurring income. GAAP net investment income declined to $34.4 million ($0.39 per share) from $36.7 million ($0.42 per share) QoQ, while NAV per share fell to $15.69 from $16.30 QoQ amid realized and unrealized losses of $53.3 million. However, the company originated $204.1 million in new investment commitments at 9.2% weighted average yield, received $334.1 million in proceeds leading to net portfolio contraction, reduced non-accrual investments to 2.6% of debt at fair value from 3.1% QoQ, and declared total cash distributions of $0.34 per share payable June 30, 2026.

• ·Unfunded investment commitments of $276.7 million ($249.6 million excluding JVs) as of Mar 31, 2026.
• ·Liquidity: $620.0 million undrawn credit facility capacity as of Mar 31, 2026.
• ·SLF JV I investment at fair value $112.8 million (down 6.7% QoQ); Glick JV $41.5 million (down 5.4% QoQ).
• ·91.0% of portfolio floating-rate as of Mar 31, 2026.
• ·Quarterly distribution $0.30/share + supplemental $0.04/share, record date June 15, 2026.

05-05-2026

News Corporation disclosed via 8-K the provision of information to the Australian Securities Exchange (ASX) regarding its ongoing $1 billion stock repurchase program authorizing purchases of Class A (NWSA) and Class B (NWS) common stock. The company provides daily disclosures to ASX on any repurchase transactions and includes such information in its quarterly and annual reports. Exhibits 99.1 and 99.2 contain the specific ASX disclosures, which include forward-looking statements about potential repurchases subject to market conditions.

05-05-2026

Integra LifeSciences reported first quarter 2026 revenues of $391.9 million, up 2.4% reported and 1.3% organic YoY, with GAAP gross margin improving to 55.4% from 50.8% and adjusted EBITDA rising to $76.2 million (19.4% of revenue) from $63.6 million (16.6%). Adjusted EPS increased to $0.54 from $0.41, though GAAP EPS was $(0.06) versus $(0.33). While Tissue Reconstruction revenues grew 6.4% organically to $108.8 million, Specialty Surgery (~70% of revenues) declined 0.6% organically to $283.1 million, with Instruments down 7.7% and ENT down 3.8%.

• ·GAAP net loss of $(4.6) million in Q1 2026 vs $(25.3) million in Q1 2025
• ·Q2 2026 revenue guidance: $410M to $425M (organic growth -1.5% to 2.1%)
• ·FY2026 revenue guidance: $1.662B to $1.702B (organic growth 0.8% to 3.3%)
• ·FY2026 adjusted EPS guidance updated to $2.40 to $2.50
• ·Consolidated total leverage ratio 4.1x at quarter end

05-05-2026

IDEXX Laboratories reported first quarter 2026 revenue of $1,141 million, up 14% as reported and 11% organic, driven by Companion Animal Group (CAG) growth of 15% reported and 12% organic, including double-digit CAG Diagnostics recurring revenue growth. EPS rose 17% as reported to $3.47, with operating margin expanding 10 basis points to 31.8%, though impacted by a $5 million equity investment loss and flat organic growth in rapid assay products. The company raised its full-year 2026 revenue guidance to $4,675-$4,760 million (8.6%-10.6% reported growth) and EPS outlook to $14.45-$14.90.

• ·Water revenues grew 11% reported and 7% organic.
• ·LPD revenues increased 14% reported and 7% organic.
• ·2026 Annual Meeting of Shareholders scheduled for May 12, 2026 virtually.
• ·Headquartered in Westbrook, Maine; operates in over 175 countries.

05-05-2026

Harel Insurance Investments & Financial Services Ltd. filed its 13F-HR on May 5, 2026, disclosing U.S. equity holdings as of March 31, 2026, with no reported changes in positions from prior periods in this filing. Key holdings include Alphabet Inc. Class A (713758 thousand USD value, 2482119 shares), Apple Inc. (589035 thousand USD, 2320981 shares), Amazon.com Inc. (406447 thousand USD, 1951562 shares), Camtek Ltd. (349008 thousand USD, 2302009 shares), and Broadcom Inc. (227960 thousand USD, 736534 shares). The filing notes that portions are held through subsidiaries like Harel Insurance Company Ltd. and others, with disclaimers on beneficial ownership beyond pecuniary interest.

• ·Report period end date: 2026-03-31
• ·Filing as of date: 2026-05-05
• ·Securities partially held for public through provident funds, mutual funds, pension funds, and insurance policies managed by subsidiaries
• ·Subsidiaries operate under independent management with independent voting and investment decisions

05-05-2026

LiveWire Group, Inc. reported Q1 2026 revenue of $5.1 million, up 86% YoY from $2.7 million, driven by electric motorcycle unit sales surging 176% and STACYC units increasing 101%, leading to a 14% reduction in consolidated operating loss to $17.7 million. Free cash flow improved 25% to ($13.6) million. However, the company posted a net loss of $18.1 million, slightly improved from $19.3 million YoY, with cash and equivalents declining to $67.5 million from $82.8 million at year-end.

• ·Maintained #1 position as retailer of U.S. electric on-road motorcycles.
• ·76% market share in U.S. electric motorcycle 50+ kilowatt on-road EV segment.
• ·Company reiterates full-year 2026 guidance.
• ·Cash and cash equivalents decreased from $82.8M (Dec 31, 2025) to $67.5M (Mar 31, 2026).
• ·Shareholders' equity declined from $46.0M (Dec 31, 2025) to $28.3M (Mar 31, 2026).

05-05-2026

LCI Industries reported first quarter 2026 net sales up 4.3% YoY to $1.1 billion, operating profit margin expanded 90 bps to 8.7%, net income increased 27% to $63 million, and adjusted EBITDA rose 13% to $125 million. However, RV OEM net sales declined 4% to $509.8 million due to lower North American travel trailer and fifth-wheel shipments, and Aftermarket segment operating profit margin contracted to 7.8% from 8.7% amid higher material costs. The company tightened its 2026 outlook with revenue of $4.2-$4.3 billion and adjusted EPS of $8.75-$9.25, but lowered North American RV wholesale shipments to 315,000-330,000.

• ·Cash flows from operations of $255 million for LTM ended March 31, 2026
• ·$28 million returned to shareholders via dividends in Q1 2026
• ·$9.7 million capital expenditures in Q1 2026
• ·April 2026 net sales outlook of approximately $374 million, down 4% YoY
• ·2026 adjusted EPS outlook of $8.75 to $9.25
• ·Towable RV content per unit up 13% to $5,826
• ·Top five new innovative products expected to contribute $270 million to annualized sales

05-05-2026

Bowhead Specialty Holdings Inc. reported robust Q1 2026 financial results, with gross written premiums surging 24.0% YoY to $216.7 million, led by 313.9% growth in Baleen Specialty to $11.4 million and increases in Casualty (20.4% to $147.3 million), Healthcare Liability (28.0% to $30.4 million), and Professional Liability (6.4% to $27.7 million). Net income rose 40.1% to $16.0 million, supported by a 43.5% increase in net investment income to $18.0 million and an improved expense ratio of 28.4% (down 2.0 points YoY), resulting in a combined ratio of 95.3% (improved from 97.3%); however, the loss ratio remained flat at 66.9% YoY.

• ·Book value per share $13.98 and diluted book value per share $13.80 as of March 31, 2026.
• ·Investment portfolio book yield 4.6% and new money rate 4.7%; weighted average effective duration 3.2 years; average rating 'AA-'.
• ·Return on equity 14.1% and adjusted return on equity 14.1% for Q1 2026 (up from 12.0% and 12.1% YoY).
• ·Ceded written premiums increased 31.5% YoY to $76.4 million.
• ·Interest expense and financing fees $3.2 million, up 1180.2% YoY.

05-05-2026

Pfizer reported first-quarter 2026 revenues of $14.5 billion, up 2% operationally year-over-year, with launched and acquired products growing 22% operationally and non-COVID revenues up 7% operationally, driven by strong performances in Padcev (+39%), Oncology biosimilars (+52%), and Nurtec (+41%); however, this was partially offset by sharp declines in Comirnaty (-59% operationally) and Paxlovid (-63% operationally). Reported diluted EPS fell 10% to $0.47 and adjusted diluted EPS declined 18% to $0.75. The company reaffirmed its full-year 2026 guidance, including revenues of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00.

• ·Positive Phase 3 topline results for Elrexfio in RRMM (MagnetisMM-5) and Padcev + pembrolizumab in MIBC (EV-304, 47% risk reduction, HR 0.53).
• ·FDA full approval for Braftovi + cetuximab + chemotherapy in BRAF V600E-mutant mCRC; positive PFS from BREAKWATER Cohort 3.
• ·CHMP positive opinion for Hympavzi expansion to pediatric hemophilia patients; FDA priority review sBLA with PDUFA Q2 2026.
• ·FDA priority review sBLA for perioperative Padcev + pembrolizumab in MIBC regardless of cisplatin eligibility, PDUFA August 17, 2026.
• ·Organizational changes: Transition of off-patent injectables/biosimilars to new Global Hospital and Biosimilars Division.
• ·On track to start ~20 key pivotal studies in 2026.
• ·No share repurchases in 2026 anticipated per guidance.

05-05-2026

First Business Financial Services, Inc. (FBIZ) posted an investor presentation to its website (www.firstbusiness.bank) on May 5, 2026, under the Investor Relations tab, providing an overview of the Company’s recent operating performance, financial condition, and business strategy. The presentation is intended for use by executives in interactions with shareholders, analysts, and other third parties and is furnished as Exhibit 99.1. No specific financial metrics or period-over-period comparisons are detailed in the filing.

• ·Filing includes Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits).
• ·Presentation information is 'furnished' and not deemed 'filed' under securities regulations.

05-05-2026

DFIN reported first-quarter 2026 net sales of $205.5 million, up 2.2% YoY from $201.1 million, driven by 8.4% growth in software solutions net sales to $91.7 million (44.6% of total), though partially offset by lower capital markets and investment companies compliance revenue due to reduced demand for printed materials. Net earnings increased 8.1% to $33.5 million ($1.27 per diluted share), Adjusted EBITDA rose 3.5% to $70.6 million (34.4% margin, up 50 bps), and cash flows improved significantly with operating cash flow at ($5.6) million (vs. ($37.7) million) and free cash flow at ($16.0) million (vs. ($51.0) million), albeit still negative. The company repurchased 594,782 shares for $28.3 million and authorized a new $150 million share repurchase program.

• ·Gross leverage of 0.9x and net leverage of 0.8x as of March 31, 2026.
• ·Q2 2026 guidance: total net sales $215M to $225M, Adjusted EBITDA margin 34% to 36%, capital markets transactional net sales $40M to $45M.
• ·Conference call scheduled for May 5, 2026 at 9:00 a.m. Eastern time.
• ·Previous share repurchase authorization had $25.5 million remaining as of March 31, 2026.

05-05-2026

Cipher Digital Inc. reported Q1 2026 revenue of $35 million, down 29% YoY from $49 million, with Adjusted EBITDA of negative $48 million and net loss widening to $114 million from $39 million. Positive operational highlights include signing a third AI data center campus lease with an investment-grade hyperscale tenant, Barber Lake and Black Pearl projects remaining on schedule, and securing a $200 million revolving credit facility. The company stated it has sufficient capital for near-term needs amid significant balance sheet growth, with total assets reaching $6.39 billion.

• ·Bitcoin holdings declined to $76.2 million (76,150 thousand) from $125.4 million as of Dec 31, 2025.
• ·Property and equipment, net increased to $1.307 billion from $633.4 million QoQ.
• ·Long-term borrowings, net rose to $4.377 billion from $2.712 billion QoQ.
• ·Stockholders’ equity decreased to $714 million from $806 million QoQ.

05-05-2026

Amalgamated Financial Corp. reported Q1 2026 net income of $25,223 thousand (up 0.8% YoY from $25,028 thousand), with net interest income growing 13.5% YoY to $80,156 thousand on higher loan ($63,471 thousand) and securities ($44,189 thousand) income. However, provision for credit losses surged to $13,488 thousand from $596 thousand, causing net interest income after provision to decline 4.7% YoY to $66,668 thousand, while non-interest expense rose 10.2% to $45,888 thousand. Total assets expanded 3.4% QoQ to $9,170,892 thousand, driven by 1.3% QoQ growth in net loans receivable to $4,965,203 thousand and 2.9% QoQ increase in deposits to $8,178,084 thousand.

• ·Earnings per common share - basic: $0.85 (Q1 2026) vs $0.82 (Q1 2025)
• ·Dividends declared: $0.17 per share (Q1 2026) vs $0.14 per share (Q1 2025)
• ·Net cash used in investing activities: $387,352 thousand (Q1 2026) vs $6,611 thousand (Q1 2025)
• ·Accumulated other comprehensive loss increased to $(36,586) thousand from $(32,088) thousand QoQ

05-05-2026

Signet Financial Management, LLC filed its quarterly 13F-HR on May 5, 2026, disclosing holdings as of March 31, 2026, with a total portfolio value of $891,965,814 across 299 positions held solely with discretionary voting authority. Top holdings include SPDR Portfolio S&P 500 ETF ($32,262,637), SPDR Portfolio Developed World ex-US ETF ($28,759,960), and SPDR S&P 500 ETF Trust ($11,186,784). No changes in voting authority or performance metrics were reported.

• ·All 299 positions held as sole discretionary with zero shared or other voting authority.
• ·Portfolio heavily weighted towards ETFs (e.g., SPDR and iShares products) and large-cap stocks.

05-05-2026

Napier Financial, LLC filed its Form 13F-HR on May 5, 2026, disclosing institutional investment holdings as of March 31, 2026, primarily consisting of common stocks and iShares ETFs. Top positions include an iShares Russell ETF valued at $54.3M, an iShares Core ETF at $39.9M, and an iShares MSCI ETF at $24.3M, alongside individual stocks like Apple Inc. ($9.1M) and Microsoft Corp. ($2.3M). The filing provides a snapshot with no prior period comparisons available.

• ·Report period end date: March 31, 2026
• ·Filing date: May 5, 2026
• ·Filer address: 30 Braintree Hill Office Park Suite 201, Braintree, MA 02184
• ·Phone: 781-884-2356
• ·Portfolio includes over 200 positions across stocks and ETFs

05-05-2026

State of New Jersey Common Pension Fund D disclosed its quarterly 13F-HR holdings as of March 31, 2026, reporting 1549 positions with a total value of $25927076128 across various equities held solely. Top holdings by share count include Apple Inc. (5024674 shares), Amazon.com Inc. (3290326 shares), AT&T Inc. (2430617 shares), Bank of America Corp. (2357682 shares), and Alphabet Inc. Cap Stk Cl A (1986061 shares). The filing was submitted on May 05, 2026, and signed by Shoaib Khan, Director; no changes or performance metrics relative to prior periods were provided.

• ·All reported holdings held with sole voting and dispositive power (no shared or none reported)
• ·Fiscal year end: 0630
• ·SEC file number: 028-13667
• ·Public document count: 2

05-05-2026

93 Financial Group, LLC filed its 13F-HR on May 5, 2026, reporting holdings as of March 31, 2026, with a total portfolio value of $224,267,731 across nine ETF positions, all held with sole voting authority. Largest holdings include Vanguard Russell 1000 Growth ETF at $65,726,100, Schwab U.S. Mid-Cap ETF at $49,014,055, and Schwab U.S. Small-Cap ETF at $46,779,408. Other positions feature Schwab Emerging Markets Equity ETF ($20,528,034), SPDR ETF ($17,456,905), and iShares Core U.S. REIT ETF ($22,310,447), with no changes in voting authority reported.

• ·All holdings reported with sole shared voting authority (SH SOLE) and no other voting authority.
• ·Filer located at 600 Unicorn Park Drive, Woburn, MA 01801.
• ·SEC file number: 028-26669.

05-05-2026

Tompkins Financial Corp (TMP) reported Q1 2026 net income of $26,074 thousand, up 32.6% YoY from $19,679 thousand, fueled by net interest income growth of 26.8% to $71,861 thousand and a reduced provision for credit losses to $1,502 thousand from $5,287 thousand. However, noninterest income plummeted 52.7% to $11,834 thousand from $25,032 thousand, primarily due to zero insurance commissions versus $11,599 thousand prior year, while comprehensive income fell to $19,030 thousand from $35,961 thousand on unrealized securities losses. Total assets edged up 0.3% QoQ to $8,695,761 thousand, with net loans increasing 0.5% to $6,419,835 thousand and deposits rising 1.7% to $7,054,172 thousand.

• ·Basic EPS $1.83 in Q1 2026 vs $1.38 in Q1 2025
• ·Diluted EPS $1.82 in Q1 2026 vs $1.37 in Q1 2025
• ·Cash dividends declared $0.67 per share in Q1 2026 vs $0.62 in Q1 2025
• ·Common stock repurchased 23,731 shares in Q1 2026 for $1,816 thousand
• ·Provision for credit losses $1,502 thousand in Q1 2026 vs $5,287 thousand in Q1 2025

05-05-2026

Principal Exchange-Traded Funds filed definitive additional proxy materials (DEFA14A) soliciting votes from shareholders of the Principal Capital Appreciation Select ETF for a Special Meeting on June 25, 2026. The solicitation, handled by Sodali & Co., encourages voting online via QR code or by phone at 1-888-457-3803, with a Proxy Statement available for details on the affecting proposal. No financial performance data or period comparisons are provided in the materials.

• ·Filing date: May 05, 2026
• ·Special Meeting date: June 25, 2026
• ·Voting hours: Monday–Friday 10:00 a.m. to 11:00 p.m. ET; Saturday 12:00 p.m. to 5:00 p.m. ET
• ·Proxy materials access: https://proxyvotinginfo.com/p/prinetf or call 1-888-457-3803

05-05-2026

Wedgewood Investors Inc /PA/ filed its 13F-HR report on May 5, 2026, disclosing 99 equity holdings totaling $87,211,298 as of March 31, 2026. The portfolio consists primarily of large-cap stocks and ETFs, with top positions including Schwab Strategic Trust Large Cap ETF, DBX ETF TRX Trackers Artificial Intelligence, Exxon Mobil Corp, Invesco QQQ Trust Unit Series, and Microsoft Corp. All holdings are under sole investment discretion, managed by President Daniel J. Teed.

• ·Filer CIK: 0001125243
• ·Report period end: 20260331
• ·State of incorporation: PA
• ·Business address: 100 State Street Ste 506, Erie PA 16507
• ·All holdings reported with SOLE investment discretion
• ·SEC file number: 028-05937

05-05-2026

Holistic Financial Partners filed its 13F-HR on May 05, 2026, disclosing holdings as of March 31, 2026, totaling $269034831 across 146 positions, all with sole voting and investment power. Top holding is Eli Lilly & Co at $62261372 (67692 shares), followed by Schwab Strategic TR Intl Eqty ETF at $13812788 (558092 shares) and First TR Exchange-Traded ALP Com Shs at $12988489 (140644 shares). No prior period comparisons or changes are provided in the filing.

• ·Report period end date: 2026-03-31
• ·Filing as of date: 2026-05-05
• ·All positions held with sole voting power (SH SOLE)
• ·Investment advisor address: 9959 Crosspoint Blvd, Indianapolis, IN 46256

05-05-2026

BayFirst Financial Corp. (BAFN) hosted a conference call on May 1, 2026, to discuss its financial results for the quarter ended March 31, 2026, with the transcript attached as Exhibit 99.1. The filing under Items 7.01 and 9.01 is for Regulation FD Disclosure and is not deemed 'filed' under the Exchange Act. An archived version of the call is available on the company's Investor Relations website at www.bayfirstfinancial.com.

• ·Filing date: May 05, 2026
• ·Date of earliest event reported: May 1, 2026
• ·Quarter reported: ended March 31, 2026

05-05-2026

Landing Point Financial Group, LLC filed its 13F-HR on May 5, 2026, disclosing $206064209 in total 13F-eligible assets across 93 holdings as of March 31, 2026. The portfolio is dominated by ETFs, with the largest position in iShares Core S&P 500 ETF at $41830804 (64039 shares), followed by Fidelity High Dividend ETF at $27407729 (496157 shares) and iShares AAA CLO Active ETF at $15459936 (298253 shares). Notable individual stock holdings include Apple Inc. at $11150826 (43937 shares) and NVIDIA Corporation at $5628508 (32274 shares), with no reported changes in sole voting authority positions.

• ·Report period end date: 03-31-2026
• ·All positions reported as sole voting authority with zero put/call options
• ·Filer address: 36350 Detroit Road, Avon, OH 44011
• ·Additional notable holdings: NVIDIA Corporation (32274 shares, $5628508), Amazon.com Inc (11617 shares, $2419442)

05-05-2026

MJP Associates Inc/ADV filed its 13F-HR on May 5, 2026, disclosing 231 holdings totaling $823650678 as of March 31, 2026. Notable positions include Vanguard S&P 500 ETF at $81862377 (136997 shares), Janus Detroit Street Trust Henderson AAA CLO ETF at $57569337 (1142929 shares), and Apple Inc. at $35407314 (139514 shares). The filing provides a snapshot of current holdings with no period-over-period comparisons available.

• ·Filing period end date: 03/31/2026
• ·Filer CIK: 0000715113
• ·Filer address: 74 Batterson Park Road Suite 103, Farmington, CT 06032
• ·Includes minor call option positions: Apple 100 SH Call, Costco 300 SH Call, Micron 300 SH Call

05-05-2026

Plante Moran Financial Advisors, LLC disclosed total holdings of $1,546,040,882 across 718 positions in its 13F-HR filing as of March 31, 2026. The portfolio features heavy ETF allocations including Vanguard Extended Market ETF at $170,972,880 and Vanguard Large-Cap ETF at $85,786,393, alongside stocks such as Microsoft Corp ($5,603,948), Amazon.com Inc ($2,933,016), and Alphabet Inc ($2,800,315). All reported positions are held solely with no shared voting or investment discretion indicated.

• ·Filing submitted on May 05, 2026 for quarter ended March 31, 2026.
• ·Headquartered at 3000 Town Center Dr., Suite 100, Southfield, MI 48075.
• ·All holdings reported as SOLE discretionary with zero shared voting or investment discretion.

05-05-2026

Louisiana-Pacific Corporation (LPX) held its annual stockholder meeting on May 1, 2026, with 63,351,275 shares represented out of 69,848,440 outstanding, representing high turnout. Stockholders elected three Class II directors (Jose A. Bayardo, Stephen E. Macadam, and Jean-Michel Ribieras), ratified Deloitte & Touche LLP as the independent auditor for 2026, and approved the advisory say-on-pay for named executives on a non-binding basis. While support was strong across proposals, notable opposition included 9,976,557 votes against Stephen E. Macadam and 6,387,571 against executive compensation.

• ·Director Jose A. Bayardo: 52,852,149 For, 6,479,096 Against, 130,266 Abstentions
• ·Director Stephen E. Macadam: 49,437,570 For, 9,976,557 Against, 47,384 Abstentions
• ·Director Jean-Michel Ribieras: 52,787,955 For, 6,617,369 Against, 56,187 Abstentions
• ·Auditor ratification: 767,037 Against, 33,812 Abstentions
• ·Say-on-pay: 6,387,571 Against, 59,463 Abstentions
• ·Proxy statement filed March 20, 2026

05-05-2026

Federal Home Loan Bank of Cincinnati filed an 8-K on May 5, 2026, reporting Consolidated Bonds committed to be issued on trade dates April 29-30, 2026, for which it is the primary obligor, totaling $6,805,000,000 in par value across 14 bonds. These include fixed-rate callable bonds with coupons from 3.805% to 4.300% and variable single index floaters, with maturities ranging from 2026 to 2029. The obligations are joint and several among the 11 Federal Home Loan Banks, backed solely by their resources, with no U.S. government guarantee.

• ·Consolidated Obligations sold through Office of Finance using authorized securities dealers.
• ·Schedule A excludes Consolidated Discount Notes due to short-term maturities (max 360 days).
• ·Par amounts reported at par; may differ from GAAP financial statements due to discounts/premiums.
• ·Bonds include Optional Principal Redemption (European/Bermudan) and Non-Callable types; Fixed Constant and Variable Single Index Floater rate types.

05-05-2026

For the three months ended March 31, 2026, Ridgewood Energy U Fund LLC reported oil and gas revenue of $800 thousand, up 12% YoY from $712 thousand, driving net income to $388 thousand (+8% YoY) and income from operations to $355 thousand (+8% YoY). However, total expenses increased 16% YoY to $445 thousand, led by higher depletion and amortization (+20%) and operating expenses (+22%), while general and administrative expenses declined slightly; other income remained flat at $33 thousand. Operating cash flow strengthened significantly to $490 thousand (+119% YoY), though members' capital decreased to $4,656 thousand amid distributions.

• ·Proved oil and gas properties net: $2,280 thousand at March 31, 2026 (down from $2,519 thousand at Dec 31, 2025)
• ·Distributions in Q1 2026: $463 thousand (vs $197 thousand in Q1 2025)
• ·Shareholder net income interest: $307 thousand Q1 2026 (+7% YoY from $287 thousand)
• ·Cash and cash equivalents increased QoQ to $1,800 thousand from $1,780 thousand

05-05-2026

Ridgewood Energy W Fund LLC reported total revenue of $464 thousand for the three months ended March 31, 2026, down 42% YoY from $796 thousand due to lower oil and gas revenue of $413 thousand (versus $699 thousand prior year), while other revenue fell to $51 thousand from $97 thousand. Net income declined 54% to $73 thousand from $159 thousand, despite total expenses dropping 36% to $428 thousand and interest income rising 19% to $37 thousand; shareholder net income per share was $122 versus $271. Total assets grew to $7.031 million from $6.486 million at year-end 2025, driven by higher net oil and gas properties, though members' capital slightly decreased to $4.391 million.

• ·Management fees to affiliate remained flat at $127 thousand YoY.
• ·Distributions totaled $152 thousand in Q1 2026 versus $386 thousand in Q1 2025.
• ·Net cash used in investing activities was $68 thousand in Q1 2026 versus $16 thousand prior year.

05-05-2026

Ridgewood Energy S Fund LLC reported total revenue of $271 thousand for Q1 2026, a 42% YoY decline from $467 thousand, driven by oil and gas revenue dropping 41% to $240 thousand and other revenue falling 48% to $31 thousand. While total expenses decreased 39% YoY to $224 thousand, including depletion and amortization down 49% and operating expenses down 50%, net income declined 40% to $73 thousand from $121 thousand. Total assets grew 7% QoQ to $4,696 thousand, supported by a 31% increase in net oil and gas properties to $1,504 thousand, though cash decreased 10% QoQ to $1,152 thousand.

• ·Manager interest net income: $24 thousand Q1 2026 vs $45 thousand Q1 2025 (-47%)
• ·Shareholder interest net income: $49 thousand Q1 2026 vs $76 thousand Q1 2025 (-36%); per share $58 vs $91
• ·Distributions: $126 thousand Q1 2026 vs $270 thousand Q1 2025
• ·Capital expenditures: $16 thousand in Q1 2026
• ·Shares outstanding: 839.5395 (unchanged)

05-05-2026

For the three months ended March 31, 2026, Ridgewood Energy O Fund LLC reported total revenue of $1,251 thousand, down 15.9% YoY from $1,487 thousand, driven by declines in oil and gas revenue (13.7% lower at $1,199 thousand) and other revenue (46.9% lower at $52 thousand). Total expenses fell 16.9% to $918 thousand, with notable reductions in depletion and amortization (26.6% lower) and operating expenses (15.2% lower), but income from operations still declined 12.8% to $333 thousand, leading to net income of $396 thousand, down 10.8% YoY. Total assets grew slightly to $12,813 thousand from $12,235 thousand at year-end 2025, while cash and equivalents decreased to $2,949 thousand.

• ·Manager interest in net income: $104 thousand (Q1 2026) vs $130 thousand (Q1 2025)
• ·Shareholder interest in net income: $292 thousand (Q1 2026) vs $314 thousand (Q1 2025); Net income per share: $335 (Q1 2026) vs $361 (Q1 2025)
• ·Oil and gas properties net: $4,763 thousand (Mar 31, 2026) vs $4,415 thousand (Dec 31, 2025)
• ·Total members' capital: $8,538 thousand (Mar 31, 2026) vs $8,667 thousand (Dec 31, 2025)

05-05-2026

For the three months ended March 31, 2026, Ridgewood Energy X Fund, LLC reported oil and gas revenue of $800 thousand, up 12% YoY from $712 thousand, driving net income to $278 thousand (+15% YoY) and shareholder net income per share to $458 (+15% YoY). However, total expenses increased 11% YoY to $588 thousand, oil and gas properties net declined to $2,280 thousand from $2,519 thousand (QoQ), and total members' capital decreased slightly to $9,388 thousand. Operating cash flow improved sharply to $382 thousand from $148 thousand YoY.

• ·Depletion and amortization expense increased to $176 thousand from $139 thousand YoY.
• ·Management fees to affiliate decreased slightly to $162 thousand from $173 thousand YoY.
• ·Distributions totaled $383 thousand in Q1 2026 vs $312 thousand in Q1 2025.
• ·Cash and cash equivalents increased $18 thousand QoQ to $6,359 thousand.

05-05-2026

For the three months ended March 31, 2026, Ridgewood Energy Y Fund LLC reported total revenue of $1,145 thousand, down 12% YoY from $1,304 thousand, driven by declines in oil and gas revenue (-10%) and other revenue (-48%). While total expenses decreased 12% YoY to $813 thousand, supporting a reduction in depletion and operating costs, net income fell 11% YoY to $385 thousand from $433 thousand. Total assets grew modestly to $10,744 thousand from $10,328 thousand at year-end 2025, with members' capital at $6,230 thousand.

• ·Cash flows from operating activities: $441 thousand in Q1 2026 vs $481 thousand in Q1 2025.
• ·Distributions: $470 thousand in Q1 2026 vs $349 thousand in Q1 2025.
• ·Net cash used in investing activities: $82 thousand in Q1 2026 vs $468 thousand in Q1 2025.
• ·Manager interest net income: $95 thousand Q1 2026 vs $113 thousand Q1 2025.
• ·Shareholder interest net income: $290 thousand Q1 2026 vs $320 thousand Q1 2025; net income per share $589 vs $649.

05-05-2026

Ridgewood Energy V Fund LLC reported total revenue of $300 thousand for Q1 2026, a 42% YoY decline from $517 thousand, driven by oil and gas revenue dropping 41% to $266 thousand amid lower production volumes. Net income fell 43% YoY to $79 thousand from $139 thousand, with income from operations down 48% to $60 thousand, though general and administrative expenses remained relatively flat at $77 thousand (up 5.5%). Total assets increased 13% QoQ to $4,260 thousand, supported by net oil and gas properties rising to $1,638 thousand.

• ·Cash and cash equivalents decreased QoQ to $1,447 thousand from $1,501 thousand.
• ·Net cash provided by operating activities sharply declined 90% YoY to $40 thousand.
• ·Capital expenditures for oil and gas properties were $15 thousand in Q1 2026.
• ·Shareholder net income per share was $102 in Q1 2026 vs $174 in Q1 2025.

05-05-2026

Ridgewood Energy Q Fund LLC reported total revenue of $365 thousand for Q1 2026, down 41.6% YoY from $625 thousand, driven by a 40.9% drop in oil and gas revenue to $325 thousand and 46.7% decline in other revenue to $40 thousand. Net income fell 36.7% to $133 thousand from $210 thousand, although total expenses decreased 40% to $264 thousand and interest income rose 28% to $32 thousand. Cash from operations plummeted 84.1% to $80 thousand, while shareholders' interest in net income declined to $97 thousand ($116 per share) from $145 thousand ($175 per share).

• ·Oil and gas properties, net: $1,891 thousand as of March 31, 2026 (up from $1,441 thousand at December 31, 2025).
• ·Total members' capital: $4,027 thousand as of March 31, 2026 (down from $4,087 thousand at December 31, 2025).
• ·Distributions: $193 thousand in Q1 2026 (down from $384 thousand in Q1 2025).
• ·Capital expenditures for oil and gas properties: $19 thousand in Q1 2026.

05-05-2026

For the three months ended March 31, 2026, Ridgewood Energy T Fund LLC reported total revenue of $255 thousand, a 42% YoY decline from $438 thousand, driven by oil and gas revenue dropping 41% to $226 thousand, while other revenue fell 47% to $29 thousand. Total expenses decreased 40% to $213 thousand, with operating expenses down 51% to $50 thousand and depletion down 50% to $90 thousand, but G&A expenses were relatively flat up slightly to $73 thousand; net income declined 40% to $61 thousand from $102 thousand. Cash provided by operating activities dropped sharply to $27 thousand from $283 thousand.

• ·Cash and cash equivalents decreased to $1,375 thousand from $1,413 thousand at Dec 31, 2025.
• ·Total assets increased to $3,992 thousand from $3,579 thousand at Dec 31, 2025.
• ·Net cash provided by operating activities fell to $27 thousand from $283 thousand YoY.
• ·Capital expenditures for oil and gas properties: $15 thousand in Q1 2026.
• ·971.6054 shareholder shares authorized, issued and outstanding.
• ·Net income per share for shareholders: $40 in Q1 2026 vs $64 in Q1 2025.